Interstitial fibrosis and microvascular disease of the heart in uremia: Amelioration by a calcimimetic

Laboratory Investigation

Volumn 89, Issue 5, 2009, Pages 520-530

  Koleganova, Nadezda ^a   Piecha, Grzegorz ^a,b   Ritz, Eberhard ^a   Bekeredjian, Raffi ^a   Schirmacher, Peter ^a   Schmitt, Claus Peter ^c   Gross, Marie Luise ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Calcimimetics; Cardiac remodeling; Chronic renal failure; Secondary hyperparathyroidism

Indexed keywords

3 NITROTYROSINE; ALBUMIN; ANGIOTENSIN II; CALCIMIMETIC AGENT; CALCIUM; CALCIUM SENSING RECEPTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CREATININE; HEAT SHOCK PROTEIN 70; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N [1 [4 (4 FLUOROPHENOXY)BUTYL] 4 PIPERIDINYL] N METHYL 2 BENZOTHIAZOLAMINE; PHOSPHATE; R 568; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANILINE DERIVATIVE; BIOLOGICAL MARKER; N (2 CHLOROPHENYLPROPYL) 1 (3 METHOXYPHENYL)ETHYLAMINE; N-(2-CHLOROPHENYLPROPYL)-1-(3-METHOXYPHENYL)ETHYLAMINE; PHOSPHORUS;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CAPILLARY DENSITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ECHOCARDIOGRAPHY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; IMMUNOHISTOCHEMISTRY; MALE; MICROANGIOPATHY; NEPHRECTOMY; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RAT; UREMIA; WESTERN BLOTTING; ANIMAL; CAPILLARY; CORONARY BLOOD VESSEL; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; FIBROSIS; HEART; HEART CONTRACTION; HEART DISEASE; HEART MUSCLE; METABOLISM; ORGAN SIZE; OXIDATIVE STRESS; PATHOLOGY; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM;

ANILINE COMPOUNDS; ANIMALS; BIOLOGICAL MARKERS; CALCIUM; CAPILLARIES; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; FIBROSIS; HEART; HEART DISEASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCARDIAL CONTRACTION; MYOCARDIUM; NEPHRECTOMY; ORGAN SIZE; OXIDATIVE STRESS; PHOSPHORUS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCIUM-SENSING; UREMIA;

EID: 65649087894     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.7     Document Type: Article

References (43)

1. Dennis VW. Coronary heart disease in patients with chronic kidney disease. J Am Soc Nephrol 2005;16:S103-S106.
2. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
3. Tyralla K, Amann K. Morphology of the heart and arteries in renal failure. Kidney Int 2003;63:S80-S83.
4. Amann K, Breitbach M, Ritz E, et al. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998;9:1018-1022.
5. Amann K, Kronenberg G, Gehlen F, et al. Cardiac remodelling in experimental renal failure an immunohistochemical study. Nephrol Dial Transplant 1998;13:1958-1966.
6. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999;56:S14-S19.
7. Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004;66:2010-2016.
8. Foley RN, Li S, Liu J, et al. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992-2002. J Am Soc Nephrol 2005;16:210-218.
9. Smogorzewski M, Perna AF, Borum PR, et al. Fatty acid oxidation in the myocardium: effects of parathyroid hormone and CRF. Kidney Int 1988;34:797-803.
10. Baczynski R, Massry SG, Kohan R, et al. Effect of parathyroid hormone on myocardial energy metabolism in the rat. Kidney Int 1985;27:718-725.
11. Amann K, Ritz E, Wiest G, et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994;4:1814-1819.
12. Amann K, Tornig J, Flechtenmacher C, et al. Blood- pressureindependent wall thickening of intramyocardial arterioles in experimental uraemia: evidence for a permissive action of PTH. Nephrol Dial Transplant 1995;10:2043-2048.
13. Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 2006;109:339-365.
14. Ogata H, Ritz E, Odoni G, et al. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003;14:959-967.
15. Piecha G, Koleganova N, Gross ML, et al. Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination.Am J Physiol Renal Physiol 2008;295:F137-F144.
16. Amann K, Munter K, Wessels S, et al. Endothelin a receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals.J Am Soc Nephrol 2000;11:1702-1711.
17. Mattfeldt T, Mall G, Gharehbaghi H, et al. Estimation of surface area and length with the orientator. J Microsc 1990;159:301-317.
18. Tornig J, Amann K, Ritz E, et al. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 1996;7:667-675.
19. Henquell L, Honig C. Intercapillary distances and capillary reserve in right and left ventricles: significance for control of tissue pO2. Microvasc Res 1976;12:35-41.
20. Tornig J, Gross M-L, Simonaviciene A, et al. Hypertrophy of intramyocardial arteriolar smooth muscle cells in experimental renal failure. J Am Soc Nephrol 1999;10:77-83.
21. Schwarz U, Amann K, Orth SR, et al. Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998;53:1696-1705.
22. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
23. Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083.
24. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 2005;68:1973-1981.
25. Odenwald T, Nakagawa K, Hadtstein C, et al. Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J Am Soc Nephrol 2006;17:655-662.
26. Selvetella G, Hirsch E, Notte A, et al. Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 2004;63:373-380.
27. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008;358:1370-1380.
28. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 2007;116:1413-1423.
29. Holstein DM, Berg KA, Leeb-Lundberg LMF, et al. Calcium-sensing receptor-mediated ERK1/2 activation requires G{alpha}i2 coupling and dynamin-independent receptor internalization. J Biol Chem 2004;279:10060-10069.
30. Opie LH, Commerford PJ, Gersh BJ, et al. Controversies in ventricular remodelling. Lancet 2006;367:356-367.
31. Bueno OF, De Windt LJ, Tymitz KM, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000;19:6341-6350.
32. Yue T-L, Wang C, Gu J-L, et al. Inhibition of extracellular signalregulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 2000;86:692-699.
33. Li Z, Ma JY, Kerr I, et al. Selective inhibition of p38{alpha} MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury. Am J Physiol Heart Circ Physiol 2006;291:H1972-H1977.
34. Kyoi S, Otani H, Matsuhisa S, et al. Opposing effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster. Cardiovasc Res 2006;69:888-898.
35. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
36. Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/ tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089-2096.
37. Sasso FC, Torella D, Carbonara O, et al. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 2005;46:827-834.
38. Murdoch CE, Zhang M, Cave AC, et al. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 2006;71:208-215.
39. Brown EM. The calcium-sensing receptor (CaR) and its disorders. Hormones (Athens) 2002;1:10-21.
40. Tfelt-Hansen J, Hansen JL, Smajilovic S, et al. Calcium receptor is functionally expressed in rat neonatal ventricular cardiomyocytes. Am J Physiol Heart Circ Physiol 2006;290:H1165-H1171.
41. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:1598-1606.
42. Mizobuchi M, Hatamura I, Ogata H, et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 2004;15:2579-2587.
43. Ortiz-Capisano MC, Ortiz PA, Garvin JL, et al. Expression and function of the calcium-sensing receptor in juxtaglomerular cells. Hypertension 2007;50:737-743.